Jefferies weighs in on all the drama with ViroPharma (VPHM), cutting earnings estimates and its...

|By:, SA News Editor

Jefferies weighs in on all the drama with ViroPharma (VPHM), cutting earnings estimates and its price target but keeping a Buy rating in place. Analysts call the sharp selloff in shares after the FDA granted approval for generic versions of Vancocin an "overreaction" because Cinryze is the critical part of the VPHM story.